Tonix Pharmaceuticals (TNXP) Q2 2026 earnings summary

Executive summary

• Net product revenue for Q2 2026 reached $13.5 million, up from $2.0 million in Q2 2025, driven by TONMYA's successful launch and 197% quarter-over-quarter sales growth, with migraine products contributing $2.5 million.

• TONMYA is the first FDA-approved fibromyalgia treatment in over 15 years, addressing a large unmet need with a differentiated, non-opioid profile and expanded coverage to 136 million lives.

• Expanded sales force and market access coverage, targeting 150 representatives by September 2026, to drive further adoption and growth.

• Advanced clinical pipeline with first patient enrolled in Phase 2 HORIZON study for TNX-102 SL in MDD and FDA alignment for TNX-4800 Lyme disease prevention, with Phase 2 study set to begin in Q1 2027.

• Cash and cash equivalents stood at $176.2 million as of June 30, 2026, with no debt.

Financial highlights

• Net product revenue for Q2 2026 was $13.5 million, up from $2.0 million in Q2 2025; TONMYA contributed $11.0 million, with Zembrace SymTouch and Tosymra adding $2.5 million.

• Cost of sales decreased to $0.7 million from $3.3 million year-over-year, reflecting product mix changes and prior write-offs.

• R&D expenses rose to $19.4 million (from $10.8 million), and SG&A expenses increased to $36.0 million (from $16.2 million), driven by pipeline prioritization and launch investments.

• Net loss for Q2 2026 was $40.6 million ($2.44 per share), compared to $28.3 million ($3.86 per share) in Q2 2025.

• Cash and cash equivalents at June 30, 2026: $176.2 million; working capital: $172.6 million.

Outlook and guidance

• Cash resources, including recent equity proceeds, are expected to fund operations into early Q2 2027.

• Anticipate continued fluctuations in gross-to-net and margins as coverage expands, with stabilization expected as market access matures.

• Expect further sales growth and patient access improvements as new coverage agreements take effect and sales force expansion is completed by September.

• Phase 2 clinical studies for TNX-102 SL in MDD and TNX-4800 for Lyme disease prevention are key near-term milestones, with TNX-4800 study to begin enrollment in Q1 2027.

• Management expects continued operating losses and increased R&D spending in the near term; additional capital will be required to fund future operations.